Astrazeneca ADR Stock
Price
Target price
-
-
-
-
-
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Astrazeneca ADR Stock
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Astrazeneca ADR stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Astrazeneca ADR in the next few years
Pros
?
C******** o* t** e**********
?
S********** s********
?
B****
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Astrazeneca ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Astrazeneca ADR | - | - | - | - | - | - | - |
| GSK plc ADR | - | 0.442% | -2.575% | 40.123% | 8.612% | 44.586% | 5.581% |
| Bayer AG ADR | -0.820% | 4.310% | -10.370% | 77.941% | 37.500% | -4.724% | 6.140% |
| Novartis AG | 2.060% | 0.059% | -1.841% | 36.532% | 14.605% | 69.300% | 69.300% |
News
Royalty Pharma Q2 Earnings Call Highlights
Key Points
- Interested in Royalty Pharma PLC? Here are five stocks we like better.
- Royalty Pharma raised its 2026 outlook for the second consecutive quarter, now forecasting portfolio receipts
SOPHiA GENETICS Q2 Earnings Call Highlights
Key Points
- Interested in SOPHiA GENETICS SA? Here are five stocks we like better.
- Q2 revenue rose 27% to $23.3 million, while patient analyses reached a record 115,000 and the adjusted EBITDA
Astrazeneca Q2 Earnings Call Highlights
Key Points
- Interested in Astrazeneca Plc? Here are five stocks we like better.
- Solid first-half performance: AstraZeneca reported revenue growth of 6% at constant exchange rates and 11%